Kansas City Chapter Meetings and Events
9th Annual Kansas City VisionWalk
Saturday, June 18, 2016
Frank A. Theis Park
On March 13, the Foundation Fighting Blindness was proud to welcome Dr. David Chacko from the Grene Vision Group to speak at Envision in Wichita.
Dr. Chacko specializes in diseases of the retina and vitreous, with clinical focus on surgery of the vitreous and retina, macular degeneration, and diabetic retinopathy. He gave a very entertaining presentation on the medical treatment and research of retinal diseases. Dr. Chacko has been funded in the past by FFB for his research.
Guests of the meeting also received a tour of the Envision facilities, which offers a full range of services for the blind and visually impaired. Within Envision Industries, almost 50 percent of the 400 Envision employees are blind or vision impaired, making Envision the nation's second largest employer of individuals who are blind or vision impaired. Employees with vision impairments work in manufacturing, retail, print, customer service and administrative careers. The Envision Vision Rehabilitation Center helps patients realize their best possible functional vision by combining a comprehensive vision rehabilitation program with adaptive aids, training and resources.
The Kansas City Chapter was excited to tour the renowned lab facilities of the Vision Research Center of Kansas City at the UMKC School of Medicine on August 24, 2012.
Dr. Peter Koulen, a professor and Felix and Carmen Sabates Missouri Endowed Chair in Vision Research with the Departments of Ophthalmology and Basic Medical Science at UMKC, led the tour. We were fortunate to have some time with the doctor, who followed the tour with a question‐and‐answer session related to eye diseases.
At the Vision Research Center (VRC), scientists are at the cutting edge of vision research, attracting the brightest minds in the field to test new ideas and concepts using state‐of‐the‐art equipment to develop cures for diseases that affect the retina, including age‐related macular degeneration, diabetic retinopathy, and glaucoma.